Prodigiosin regulates cancer metabolism through interaction with GLUT1

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cancer cells rely heavily on glycolysis for ATP production, even with oxygen present, which fuels their proliferation and metastasis.
• Targeting cancer cell glycolysis presents a viable strategy for developing effective cancer treatments.
• Prodigiosin (PDG), a natural compound, exhibits anticancer properties, but its specific mechanisms and molecular targets in cancer metabolism are not fully understood.

Purpose of the Study:

• To investigate the anticancer activity of Prodigiosin (PDG).
• To elucidate the mechanism by which PDG affects cancer cell metabolism.
• To explore PDG's potential as a therapeutic agent by understanding its impact on glucose metabolism.

Main Methods:

• Assessed the effect of PDG on intracellular ATP production rates and levels in cancer cells.
• Investigated PDG's impact on glycolysis and mitochondrial oxidative phosphorylation.
• Examined PDG's interaction with glucose transporter 1 (GLUT1) at the molecular level in HCT116 cells, analyzing its effects on GLUT1 mRNA and protein expression.

Main Results:

• PDG significantly suppressed intracellular ATP production in cancer cells.
• PDG inhibited both glycolysis and mitochondrial oxidative phosphorylation, thereby reducing ATP generation from these pathways.
• PDG directly interacted with glucose transporter 1, inhibiting cellular glucose uptake without altering GLUT1 mRNA or protein levels in HCT116 cells.

Conclusions:

• PDG effectively regulates cancer cell metabolism by suppressing ATP production through inhibition of glycolysis and mitochondrial respiration.
• PDG's direct interaction with glucose transporter 1 highlights a novel mechanism for controlling glucose uptake in cancer.
• These findings suggest that PDG holds therapeutic potential for cancer treatment by targeting critical metabolic pathways.